Regeneron beats estimates; seeks early FDA approval of Eylea

10:15 AM ET Tue, 6 Aug 2013

Leonard Schleifer, Regeneron Pharmaceuticals president and CEO, breaks down the company's better-than-expected earnings, and positive results from its phase three trials of a drug designed to improve vision in patients with diabetic macular edema.